The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.

Barbee MS, Nooka A, Kaufman JL, Kim S, Chen Z, Heffner LT Jr, Lonial S, Harvey RD.
Cancer. 2014 Nov 6. doi: 10.1002/cncr.29136. [Epub ahead of print]
PMID: 25377852 [PubMed - as supplied by publisher]
Related citations
READ MORE

Posted: November 25, 2014

Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Dimopoulos MA, Swern AS, Li JS, Hussein M, Weiss L, Nagarwala Y, Baz R.
Blood Cancer J. 2014 Nov 7;4:e257. doi: 10.1038/bcj.2014.77.
PMID: 25382609 [PubMed - in process]
Related citations
READ MORE

Posted: November 25, 2014

Phase 2 study of carfilzomib, thalidomide and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.

Sonneveld P, Asselbergs E, Zweegman S, van der Holt B, Kersten MJ, Vellenga E, van Marwijk-Kooy M, Broyl A, de Weerdt O, Lonergan S, Palumbo A, Lokhorst H.
Blood. 2014 Nov 14. pii: blood-2014-05-576256. [Epub ahead of print]
PMID: 25398935 [PubMed - as supplied by publisher]
Related citations
READ MORE

Posted: November 25, 2014

Page 85 of 87« First...102030...8384858687